CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL

Cumberland Pharmaceuticals (CPIX) provided an updated webcast registration link for its October 26, 2026 call on the ifetroban DMD program.

Rhea-AI Summary

Cumberland Pharmaceuticals (CPIX) provided an updated webcast registration link for its October 26, 2026 call on the ifetroban DMD program. The webcast and conference call will begin at 4:30 p.m. Eastern Time and cover ifetroban's development as a potential treatment for cardiomyopathy, a heart muscle condition, associated with Duchenne muscular dystrophy. Webcast participants can view accompanying slides; conference-call access is audio only. A presentation copy will be available on the company's Investor Relations website.

Key Terms

cardiomyopathy, dmd

2 terms

cardiomyopathy medical

"potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy"

A condition that weakens or stiffens the heart muscle, reducing its ability to pump blood effectively; think of the heart as an engine that becomes less powerful or less flexible. For investors, cardiomyopathy matters because it can drive demand for medical treatments, affect healthcare costs, influence the value of companies developing drugs or devices, and trigger regulatory or insurance impacts that change revenues and risks across the healthcare sector.

dmd medical

"Duchenne muscular dystrophy ("DMD")"

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes progressive weakening of muscles, typically beginning in childhood, due to the absence of a critical muscle protein. For investors, DMD is important because it represents a well-defined patient population and a high unmet medical need, meaning successful therapies can command significant market value and influence regulatory decisions, trial design and long-term revenue potential—much like a niche product that fills a clear gap in demand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

A national webcasting event and conference call will be held on Monday, October 26^th at 4:30 p.m. Eastern Time to provide the update. Participants may join the presentation via webcast, to view the accompanying slides, or by conference call for audio-only access.

Webcast Participation (updated)

The link to register for the webcast participation is: 
https://edge.media-server.com/mmc/p/e4k38y5q/.

Call Participation

The link to register for the conference call participation is:

https://register-conf.media-server.com/register/BI5f9f9d5a8fef425b99857a39138a38e9.

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically
call them at the start of the conference.

Presentation Copy

A copy of the presentation will be available and can be accessed via the Investor Relations page of the Cumberland Pharmaceuticals website at:  

https://investor.cumberlandpharma.com/events-presentations.                                

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is an innovation-driven biopharmaceutical company developing new therapies to address significant unmet medical needs and improve patient outcomes.

Cumberland's clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

For more information, please visit www.cumberlandpharma.com

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-provides-updated-webcast-registration-link-for-ifetroban-dmd-program-call-302917759.html

SOURCE Cumberland Pharmaceuticals Inc.